Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COVID Vaccine Stocks: How Strong Is Moderna's Financial Position?

What Are Moderna's Risks?

The success of Moderna's COVID-19 vaccine could be just the beginning.

Could Moderna Be a Millionaire-Maker Stock?

AstraZeneca

Bank of America

BioNTech SE

Johnson & Johnson

Pfizer

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.

CDC quietly changes Covid vaccine guidance to OK mixing Pfizer and Moderna shots in 'exceptional situations'

Only 0.03% of Moderna shots administered through Jan. 10 resulted in a reported “adverse event.”

Moderna Covid-19 Vaccine Study: Allergic Reactions ‘Rare' With 2.5 Per Million Causing Anaphylaxis

Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.

Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan

Moderna surged as much as 9% on Thursday on news California has reauthorized a batch of the company's vaccine following an allergy scare.  Earlier this week, the state urged a pause on the use of lot 41L20A of the Moderna COVID-19 vaccine after seven people who received it needed medical care due to potential severe allergic reactions.

Moderna surges 9% after California authorizes vaccine batch following allergy scare (MRNA)

Developments on both sides of the Pacific Ocean seem to be driving the stock northward.

Why Moderna Is Shooting Higher Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participant dosed in Phase 1/2 study of Moderna COVID-19 Vaccine in Japan led by Takeda.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

Inoculation with Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine in California can resume after the state said it was safe to use the batch of the vaccine that was linked to adverse events in some people, the Associated Press reported Wednesday. What Happened: California's decision frees up more than 300,000 doses, which can be used by counties, cities, and hospitals grappling with a shortage of the vaccine, according to AP.

Moderna COVID-19 Vaccine Batch Gets California Nod After Review Of Adverse Events

Novavax

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today appeared first on InvestorPlace.

Covid-19 Vaccine Roundup: 5 Pharma Stocks Making the Biggest Headlines Today

Moderna stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.

Why Moderna Stock Is Already Up 25% This Year

A small number of people at one location in California experienced such effects after being inoculated with mRNA-1273.

Moderna Investigating Reports of Allergic Reactions to Its Coronavirus Vaccine

Biogen

Bio-Rad Laboratories

CVS Health

Horizon Pharma

Insulet

QuidelOrtho Corp

Teladoc

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Top Healthcare Stocks for February 2021

We just have to wait to find out if he's right.

Moderna CEO's 9 Words That Could Mean Billions for the Biotech

The vaccine batch was temporarily paused “out of an extreme abundance of caution” after fewer than 10 people had a severe reaction.

CDC, FDA Investigating California Moderna Covid-19 Vaccine Lot With ‘Higher Than Usual' Allergic Reactions

The company avoided a much-dreaded scenario.

This Is the Best News Yet for Moderna's COVID Vaccine

Advanced Micro Devices

Disney

Lemonade

Block

Here's where to invest your money right now.

$10,000 Invested in These 5 Stocks Could Make You a Fortune in 2021

Two mRNA COVID vaccines aced clinical trials. Now new virus variants are putting them to the test.

Can the Pfizer and Moderna Vaccines Beat the New Coronavirus Strains?

Its coronavirus vaccine isn't the only cause of investor celebration.

My Top COVID Stock for 2021

The wild volatility in Moderna stock before and after its vaccine approval is coming to an end but its long-term prospects are on the way up. The post Why Moderna Has More Upside Than Its Covid-19 Vaccine Implies appeared first on InvestorPlace.

Why Moderna Has More Upside Than Its Covid-19 Vaccine Implies

Over the past three months MRNA insiders have cashed out of the stock. A restriction on insider sales for certain executives was lifted in late December. This could exacerbate insider sales.

Moderna Insiders Begin To Cash Out

The company wants to see if it can still produce a sufficient response one year after inoculation.

Moderna to Test Coronavirus Vaccine Booster Shot in New Clinical Trial

Moderna Inc. (NASDAQ: MRNA) is planning to test the efficacy of COVID-19 vaccine booster shots a year after initial doses of the vaccine have been administered to an individual, CNBC reported Thursday. What Happened: The biotech company expects to begin the booster study in adult participants in July, its CEO Stéphane Bancel disclosed in a corporate presentation at the 39th Annual J.P.

News for Moderna Stock (MRNA)